NFA
CTMX icon

Nationwide Fund Advisors’s CytomX Therapeutics CTMX Stock Holding History

Nationwide Fund Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,365
Closed -$297K – 498
2017
Q3 		$297K Hold
16,365
– – ﹤0.01% 2442
2017
Q2 		$254K Buy
16,365
+4,622
+39% +$69.7K ﹤0.01% 2527
2017
Q1 		$203K Sell
11,743
-1,182
-9% -$15.6K ﹤0.01% 2578
2016
Q4 		$142K Hold
12,925
– – ﹤0.01% 2753
2016
Q3 		$203K Hold
12,925
– – ﹤0.01% 2610
2016
Q2 		$132K Buy
12,925
+7,688
+147% +$87.7K ﹤0.01% 2810
2016
Q1 		$68K Buy
5,237
+624
+14% +$8.66K ﹤0.01% 2926
2015
Q4 		$96K Buy
+4,613
New +$73K ﹤0.01% 2867

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Nationwide Fund Advisors's CTMX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2017, closing a stake of 16,365 shares — an estimated $297K sold.

Nationwide Fund Advisors first reported a position in CTMX in Q4 2015 and held it in 8 quarters. The position peaked at $297K in Q3 2017. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining CytomX Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 16,365 CytomX Therapeutics shares in Q4 2017, an estimated $297K.
  • Nationwide Fund Advisors first reported a position in CytomX Therapeutics in Q4 2015 and held it in 8 quarters.
  • Nationwide Fund Advisors's CytomX Therapeutics position peaked at $297K in Q3 2017.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.